期刊
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 48, 期 3, 页码 353-367出版社
UNIV SAO PAULO, CONJUNTO QUIMICAS
DOI: 10.1590/S1984-82502012000300002
关键词
P-glycoprotein/inhibitors; Multidrug resistence; Cluster of differentiation 243; Sphingolipids; Competitive inhibitors
P-glycoprotein (P-gp), a transmembrane permeability glycoprotein, is a member of ATP binding cassette (ABC) super family that functions specifically as a carrier mediated primary active efflux transporter. It is widely distributed throughout the body and has a diverse range of substrates. Several vital therapeutic agents are substrates to P-gp and their bioavailability is lowered or a resistance is induced because of the protein efflux. Hence P-gp inhibitors were explored for overcoming multidrug resistance and poor bioavailability problems of the therapeutic P-g,p substrates. The sensitivity of drug moieties to P-gp and vice versa can be established by various experimental models in silica, in vitro and in viva. Ever since the discovery of P-gp, the research plethora identified several chemical structures as P-gp inhibitors. The aim of this review was to emphasize on the discovery and development of newer, inert, non-toxic, and more efficient, specifically targeting P-gp inhibitors, like those among the natural herb extracts, pharmaceutical excipients and formulations, and other rational drug moieties. The applications of cellular and molecular biology knowledge, in silica designed structural databases, molecular modeling studies and quantitative structure-activity relationship (QSAR) analyses in the development of novel rational P-gp inhibitors have also been mentioned.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据